Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Neuro-Oncology
|
December 26, 2023
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group
Sabine Mueller, Jason Fangusaro, Arzu Onar Thomas, et al.
Neuro-Oncology
|
August 1, 2023
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)
Michelle Monje, Tabitha Cooney, John Glod, et al.
Cancer
|
October 10, 2013
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022)
Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, et al.
Neuro-Oncology
|
December 7, 2013
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study
Sridharan Gururangan, Jason Fangusaro, Tina Young Poussaint, et al.
Neuro-Oncology
|
February 15, 2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference
Roger J Packer, Antonio Iavarone, David T W Jones, et al.
Neuro-Oncology
|
April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Neuro-Oncology
|
March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
The Lancet. Oncology
|
April 30, 2022
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group
Giovanni Morana, Dennis Shaw, Shannon M MacDonald, et al.
Neuro-Oncology
|
February 25, 2021
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Science Signaling
|
January 24, 2019
Transcriptional repressor REST drives lineage stage-specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma
Tara H W Dobson, Rong-Hua Tao, Jyothishmathi Swaminathan, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Neuro-Oncology
|
December 26, 2023
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group
Sabine Mueller, Jason Fangusaro, Arzu Onar Thomas, et al.
Neuro-Oncology
|
August 1, 2023
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)
Michelle Monje, Tabitha Cooney, John Glod, et al.
Cancer
|
October 10, 2013
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022)
Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, et al.
Neuro-Oncology
|
December 7, 2013
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study
Sridharan Gururangan, Jason Fangusaro, Tina Young Poussaint, et al.
Neuro-Oncology
|
February 15, 2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference
Roger J Packer, Antonio Iavarone, David T W Jones, et al.
Neuro-Oncology
|
April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Neuro-Oncology
|
March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
The Lancet. Oncology
|
April 30, 2022
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group
Giovanni Morana, Dennis Shaw, Shannon M MacDonald, et al.
Neuro-Oncology
|
February 25, 2021
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Science Signaling
|
January 24, 2019
Transcriptional repressor REST drives lineage stage-specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma
Tara H W Dobson, Rong-Hua Tao, Jyothishmathi Swaminathan, et al.
Page
of 8